Compass Therapeutics (CMPX) Expected to Announce Quarterly Earnings on Thursday

Compass Therapeutics (NASDAQ:CMPX) will likely be issuing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of ($0.8180) million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 7:30 AM ET.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). On average, analysts expect Compass Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compass Therapeutics Stock Performance

Shares of CMPX stock opened at $1.83 on Tuesday. Compass Therapeutics has a 1 year low of $1.61 and a 1 year high of $6.88. The stock has a market cap of $329.56 million, a PE ratio of -4.46 and a beta of 0.79. The business’s fifty day moving average is $4.78 and its 200-day moving average is $5.14.

Wall Street Analyst Weigh In

CMPX has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Monday, April 20th. Jefferies Financial Group reiterated a “buy” rating and set a $9.00 price target on shares of Compass Therapeutics in a research report on Thursday, March 5th. Wall Street Zen cut Compass Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. William Blair restated an “outperform” rating on shares of Compass Therapeutics in a report on Thursday, March 5th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Compass Therapeutics in a report on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $13.60.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds have recently modified their holdings of CMPX. Russell Investments Group Ltd. grew its holdings in shares of Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after acquiring an additional 7,592 shares during the last quarter. Creative Planning acquired a new position in shares of Compass Therapeutics in the 2nd quarter worth $30,000. Strs Ohio acquired a new position in shares of Compass Therapeutics in the 1st quarter worth $34,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Compass Therapeutics in the third quarter worth $37,000. Finally, Virtu Financial LLC acquired a new stake in shares of Compass Therapeutics in the third quarter worth $44,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.